Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADUS Addus HomeCare	$107.03 -2.4%	$112.44	$88.96 ▼ $136.72	$1.97B	0.81	166,386 shs	136,336 shs
ARDT Ardent Health	$11.15 -3.7%	$13.88	$11.11 ▼ $20.72	$1.59B	N/A	366,160 shs	527,690 shs
CELC Celcuity	$13.59 -1.2%	$12.10	$7.58 ▼ $19.77	$514.60M	0.45	271,561 shs	293,122 shs
PGNY Progyny	$22.00 -4.4%	$21.81	$13.39 ▼ $29.65	$1.89B	1.31	1.72 million shs	1.28 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADUS Addus HomeCare	0.00%	-3.51%	-7.06%	+5.71%	-12.31%
ARDT Ardent Health	0.00%	-21.42%	-13.77%	-10.76%	+1,114,999,900.00%
CELC Celcuity	0.00%	-0.29%	+15.07%	+32.71%	-25.21%
PGNY Progyny	0.00%	-5.21%	+1.62%	+2.61%	-25.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADUS Addus HomeCare	4.9755 of 5 stars	3.6	4.0	5.0	4.0	2.5	3.1
ARDT Ardent Health	3.395 of 5 stars	3.5	0.0	0.0	2.5	0.0	3.1
CELC Celcuity	1.9277 of 5 stars	3.6	1.0	0.0	1.9	2.5	0.0
PGNY Progyny	1.7776 of 5 stars	2.3	1.0	0.0	2.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADUS Addus HomeCare	3.25	Buy	$142.57	33.21% Upside
ARDT Ardent Health	2.92	Moderate Buy	$20.30	82.06% Upside
CELC Celcuity	3.17	Buy	$28.40	108.98% Upside
PGNY Progyny	2.67	Moderate Buy	$24.82	12.81% Upside

Current Analyst Ratings Breakdown

Latest CELC, ARDT, ADUS, and PGNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	PGNY Progyny	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$24.00 ➝ $27.00
7/16/2025	ADUS Addus HomeCare	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$150.00
7/16/2025	ARDT Ardent Health	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$15.50 ➝ $14.60
7/8/2025	PGNY Progyny	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2025	PGNY Progyny	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$28.00
7/1/2025	CELC Celcuity	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/30/2025	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00
6/20/2025	ADUS Addus HomeCare	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$150.00
6/10/2025	ADUS Addus HomeCare	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$133.00
5/20/2025	ARDT Ardent Health	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$21.00 ➝ $21.00
5/19/2025	CELC Celcuity	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADUS Addus HomeCare	$1.15B	1.71	$5.39 per share	19.86	$53.52 per share	2.00
ARDT Ardent Health	$5.97B	0.27	$2.55 per share	4.38	$10.66 per share	1.05
CELC Celcuity	N/A	N/A	N/A	N/A	$3.11 per share	N/A
PGNY Progyny	$1.17B	1.62	$0.35 per share	63.75	$4.96 per share	4.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADUS Addus HomeCare	$73.60M	$4.43	24.16	19.97	1.52	6.52%	9.23%	6.96%	8/4/2025 (Estimated)
ARDT Ardent Health	$210.34M	$1.63	6.84	5.69	4.66	3.73%	16.07%	4.69%	8/13/2025 (Estimated)
CELC Celcuity	-$111.78M	-$3.03	N/A	N/A	N/A	N/A	-96.21%	-49.44%	8/13/2025 (Estimated)
PGNY Progyny	$54.34M	$0.57	38.60	33.85	2.26	4.33%	10.90%	7.20%	8/7/2025 (Estimated)

Latest CELC, ARDT, ADUS, and PGNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ARDT Ardent Health	$0.51	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	CELC Celcuity	-$0.94	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	PGNY Progyny	$0.42	N/A	N/A	N/A	$315.70 million	N/A
8/4/2025	Q2 2025	ADUS Addus HomeCare	$1.45	N/A	N/A	N/A	$345.71 million	N/A
5/14/2025	Q1 2025	CELC Celcuity	-$0.95	-$0.86	+$0.09	-$0.86	N/A	N/A
5/8/2025	Q1 2025	PGNY Progyny	$0.45	$0.17	-$0.28	$0.17	$307.86 million	$324.04 million
5/6/2025	Q1 2025	ARDT Ardent Health	$0.21	$0.29	+$0.08	$0.29	$1.50 billion	$1.50 billion
5/5/2025	Q1 2025	ADUS Addus HomeCare	$1.33	$1.42	+$0.09	$1.16	$341.66 million	$337.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADUS Addus HomeCare	N/A	N/A	N/A	N/A	N/A
ARDT Ardent Health	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
PGNY Progyny	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADUS Addus HomeCare	0.20	1.74	1.74
ARDT Ardent Health	0.70	2.12	1.98
CELC Celcuity	1.14	6.61	6.61
PGNY Progyny	N/A	2.39	2.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADUS Addus HomeCare	95.35%
ARDT Ardent Health	N/A
CELC Celcuity	63.33%
PGNY Progyny	94.93%

Insider Ownership

Company	Insider Ownership
ADUS Addus HomeCare	4.60%
ARDT Ardent Health	1.70%
CELC Celcuity	15.77%
PGNY Progyny	9.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADUS Addus HomeCare	49,703	18.40 million	17.55 million	Optionable
ARDT Ardent Health	24,900	143.04 million	140.61 million	Optionable
CELC Celcuity	40	37.87 million	31.90 million	Optionable
PGNY Progyny	310	85.72 million	77.66 million	Optionable

CELC, ARDT, ADUS, and PGNY Headlines

Recent News About These Companies

Progyny (NASDAQ:PGNY) Shares Down 4% - Here's Why

July 19 at 1:42 PM | marketbeat.com

Why Progyny (PGNY) Stock Is Falling Today

July 18 at 4:46 PM | msn.com

Edgestream Partners L.P. Sells 105,195 Shares of Progyny, Inc. (NASDAQ:PGNY)

July 18 at 5:04 AM | marketbeat.com

Progyny (NASDAQ:PGNY) Stock Price Expected to Rise, Truist Financial Analyst Says

July 17 at 11:07 AM | marketbeat.com

Principal Financial Group Inc. Raises Stake in Progyny, Inc. (NASDAQ:PGNY)

July 14, 2025 | marketbeat.com

Leerink Partnrs Has Bullish Estimate for Progyny Q2 Earnings

July 13, 2025 | americanbankingnews.com

Progyny, Inc. Partners with ŌURA to Enhance Women's Health ... - Nasdaq

July 12, 2025 | nasdaq.com

FY2026 EPS Estimates for Progyny Lifted by Leerink Partnrs

July 12, 2025 | americanbankingnews.com

Leerink Partnrs Has Bullish Forecast for Progyny Q2 Earnings

July 11, 2025 | marketbeat.com

Progyny, Inc. Partners with ŌURA to Enhance Women's Health Insights Through Wearable Technology

July 10, 2025 | quiverquant.comQ

Analysts Set Expectations for Progyny FY2026 Earnings

July 10, 2025 | marketbeat.com

Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause

July 10, 2025 | globenewswire.com

Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report - Nasdaq

July 10, 2025 | nasdaq.com

Progyny, Inc. Secures $200 Million Credit Facility to Enhance Financial Flexibility and Anticipates Positive Second Quarter Results - Nasdaq

July 10, 2025 | nasdaq.com

Which Is a Better Investment, Addus HomeCare Corporation or Progyny, Inc. Stock?

July 9, 2025 | aaii.comA

1 Value Stock with Impressive Fundamentals and 2 to Turn Down

July 9, 2025 | finance.yahoo.com

Which Is a Better Investment, Progyny, Inc. or GeneDx Holdings Corp. Stock?

July 9, 2025 | aaii.comA

Leerink Partners Upgrades Progyny (PGNY)

July 9, 2025 | msn.com

Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength?

July 9, 2025 | zacks.com

Progyny (NASDAQ:PGNY) Raised to "Strong-Buy" at Leerink Partnrs

July 9, 2025 | marketbeat.com

Progyny rises on guidance update

July 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC, ARDT, ADUS, and PGNY Company Descriptions

Addus HomeCare NASDAQ:ADUS

$107.03 -2.66 (-2.43%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$107.05 +0.02 (+0.02%)

As of 07/18/2025 07:20 PM Eastern

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.

Ardent Health NYSE:ARDT

$11.15 -0.43 (-3.71%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$11.18 +0.03 (+0.22%)

As of 07/18/2025 08:00 PM Eastern

Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

Celcuity NASDAQ:CELC

$13.59 -0.16 (-1.16%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$13.59 0.00 (0.00%)

As of 07/18/2025 04:04 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Progyny NASDAQ:PGNY

$22.00 -1.01 (-4.39%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$22.00 +0.00 (+0.02%)

As of 07/18/2025 07:34 PM Eastern

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time